Teva's Agilect Is "Approvable" For Second Time
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA continues to have concerns about issues raised in last year's approvable letter for the Parkinson's agent, Teva said.
You may also be interested in...
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.
Teva Parkinson's Agent Azilect Will Launch Within 10 Weeks
Partner Eisai will continue to co-develop the MAO-B inhibitor for Alzheimer's disease, but it is "still considering" whether it will opt to co-promote the agent for Parkinson's.
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.